Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket – Summit Therapeutics (NASDAQ:SMMT)

Shares of Summit Therapeutics Inc. SMMT rose sharply in today’s pre-market trading after the company said Ivonescimab Monotherapy reduced the risk of disease progression or death by 49% compared to pembrolizumab monotherapy in first-line treatment of patients with PD-L1 positive advanced NSCLC in China.

Summit Therapeutics shares jumped 38.8% to $16.99 in the pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

• Intelligent Bio Solutions Inc.  INBS gained 72.7% to $2.73 in pre-market trading after jumping over 20% on Friday.
• Tonix Pharmaceuticals Holding Corp. TNXP rose 48.8% to $0.2120 in today’s pre-market trading after dipping 10% on Friday.
• Nuburu, Inc. BURU gained 48% to $0.7650 in the pre-market trading session after falling 16% on Friday.
• Inspire Veterinary Partners, Inc. IVP gained 30.6% to $1.14 in pre-market trading after dipping over 25% on Friday.
• Meiwu Technology Co Ltd MWG gained 13.5% to $0.4515 in pre-market trading after declining 5% on Friday.
• Versus Systems Inc. VS shares gained 12.3% to $1.64 in pre-market trading after gaining 7% on Friday.
• Femasys Inc. FEMY gained 9.4% to $1.17 in pre-market trading.
• Savara Inc. SVRA gained 9.3% to $4.83 in pre-market trading. Savara unveiled Phase 3 IMPALA-2 trial data on molgramostim for autoimmune pulmonary alveolar proteinosis at ERS Congress 2024.
• MSP Recovery, Inc. LIFW rose 8.4% to $0.1788 in pre-market trading. LifeWallet secured a key waiver from largest creditor, launching new agreements with health plans and insurers.

Losers

• Wheeler Real Estate Investment Trust, Inc. WHLR fell 21.3% to $8.06 in pre-market trading. Wheeler Real Estate Investment Trust shares jumped 148% on Friday after the company and its subsidiary, Cedar Realty Trust, announced that the United States Court of Appeals for the Fourth Circuit affirmed a 2023 order dismissing a putative class action complaint filed against the company and Cedar by purported holders of Cedar’s preferred stock.
• Golden Minerals Company AUMN shares fell 18.2% to $0.2208 in pre-market trading after declining around 10% on Friday.
• C4 Therapeutics, Inc.. CCCC shares declined 17% to $4.48 in pre-market trading. C4 Therapeutics will reveal preliminary CFT1946 monotherapy Phase 1 clinical data at ESMO Congress 2024.
• Beneficient BENF shares declined 15.6% to $1.73 in pre-market trading after jumping over 36% on Friday.
• Eastside Distilling, Inc. EAST fell 14.7% to $1.210 in pre-market trading. Eastside Distilling announced closing of $0.4 million registered direct offering, priced at a premium to market under Nasdaq rules.
• Biomerica, Inc. BMRA fell 13.3% to $0.3007 in today’s pre-market trading after dipping 9% on Friday. Biomerica shares fell around 9% on Friday after the company announced its 10-minute at-home PSA test for early prostate cancer detection was approved by the Saudi FDA.
• Mullen Automotive, Inc. MULN shares fell 12.2% to $0.1660 in pre-market trading after dipping 12% on Friday. The company announced today that its subsidiary, Bollinger Motors, has partnered with Texas Consulting & Development to provide Bollinger B4 Class 4 trucks.
• Big Tree Cloud Holdings Limited DSY shares fell 11.1% to $3.84 in pre-market trading after gaining 5% on Friday.
• Lotus Technology Inc. LOT shares dipped 5.4% to $4.90 in pre-market trading after gaining around 6% on Friday.
• Merck & Co., Inc. MRK declined 4.8% to $112.23 in pre-market trading. Daiichi Sankyo and Merck’s Ifinatamab Deruxtecan showed response rates in extensive-stage small cell lung cancer in Phase 2 IDeate-Lung01 trial.

Now Read This: